EFFECT OF SUBSTITUTED DEXTRAN DERIVATIVE ON COMPLEMENT ACTIVATION IN-VIVO

被引:19
作者
THOMAS, H
MAILLET, F
LETOURNEUR, D
JOZEFONVICZ, J
KAZATCHKINE, MD
机构
[1] INSERM,U28,F-75014 PARIS,FRANCE
[2] UNIV PARIS 06,HOP BROUSSAIS,F-75014 PARIS,FRANCE
[3] UNIV PARIS 13,INST GALILEE,RECH MACROMOLEC LAB,CNRS,URA 502,F-93340 VILLETANEUSE,FRANCE
关键词
COMPLEMENT; DEXTRAN; SUBSTITUTED DEXTRAN DERIVATIVES; POLYMERS;
D O I
10.1016/0142-9612(95)93581-W
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
A soluble dextran derivatized with carboxylic groups (73%) and benzylamide sulphonate groups (15%), termed CMDBS 25, exhibited significant anticomplementary activity in the absence of anticoagulant activity. The polysaccharide inhibited both classical and alternative pathway-dependent complement activation in human and rat serum in vitro. Simultaneous administration of CMDBS 25 (100 mg) and crushed Sephadex G25 (20 mg) into normal Lewis rats suppressed systematic complement consumption that was induced by Sephadex in the animals by 98% for 1 h. Two consecutive injections of 100 mg of CMDBS at 1 h interval resulted in total suppression of systemic complement activation for 2 h and in 50% suppression for an additional 2 h. Infusion of CMDBS alone was well tolerated and had no effect on CH50 in serum in vivo. Our results demonstrate that CMDBS 25 exhibits anticomplementary properties in vivo and suggest that the polymer represents a potential therapeutic agent for pathological conditions associated with complement activation.
引用
收藏
页码:1163 / 1167
页数:5
相关论文
共 18 条
[1]  
BACH FH, 1993, XENO, V1, P8
[2]   THE ABILITY OF SEPHADEX TO ACTIVATE HUMAN-COMPLEMENT IS SUPPRESSED IN SPECIFICALLY SUBSTITUTED FUNCTIONAL SEPHADEX DERIVATIVES [J].
CARRENO, MP ;
LABARRE, D ;
JOZEFOWICZ, M ;
KAZATCHKINE, MD .
MOLECULAR IMMUNOLOGY, 1988, 25 (02) :165-171
[3]   MOLECULAR-WEIGHT DEPENDENCY OF THE ACQUIRED ANTICOMPLEMENTARY AND ANTICOAGULANT ACTIVITIES OF SPECIFICALLY SUBSTITUTED DEXTRANS [J].
CREPON, B ;
MAILLET, F ;
KAZATCHKINE, MD ;
JOZEFONVICZ, J .
BIOMATERIALS, 1987, 8 (04) :248-253
[4]  
DALMASSO AP, 1992, AM J PATHOL, V140, P1157
[5]  
DALMASSO AP, 1989, COMPLEMENT INFLAMM, V6, P49
[6]   THE ROLE OF COMPLEMENT IN INFLAMMATION AND PHAGOCYTOSIS [J].
FRANK, MM ;
FRIES, LF .
IMMUNOLOGY TODAY, 1991, 12 (09) :322-326
[7]   SURFACE-ASSOCIATED HEPARIN INHIBITS ZYMOSAN-INDUCED ACTIVATION OF THE HUMAN ALTERNATIVE COMPLEMENT PATHWAY BY AUGMENTING THE REGULATORY ACTION OF THE CONTROL PROTEINS ON PARTICLE-BOUND C3B [J].
KAZATCHKINE, MD ;
FEARON, DT ;
SILBERT, JE ;
AUSTEN, KF .
JOURNAL OF EXPERIMENTAL MEDICINE, 1979, 150 (05) :1202-1215
[8]   STRUCTURAL DETERMINANTS OF THE CAPACITY OF HEPARIN TO INHIBIT THE FORMATION OF THE HUMAN AMPLIFICATION C3-CONVERTASE [J].
KAZATCHKINE, MD ;
FEARON, DT ;
METCALFE, DD ;
ROSENBERG, RD ;
AUSTEN, KF .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 67 (01) :223-228
[9]  
KAZATCHKINE MD, 1985, TECHNIQUES COMPLEMEN, P22
[10]  
KAZATCHKINE MD, 1986, RETICULOENDOTHELIAL, V9, P173